Genmab A/S (NASDAQ:GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on Genmab A/S (NASDAQ:GMAB) on October 21 with a $40 price target. Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now? The analyst cited the promising clinical developments in the company’s portfolio, stating that the recent presentation at the ESMO meeting showed the efficacy of  rinatabart sesutecan (Rina-S)  for the treatment of endometrial ...